Valneva to present on CHIKUNGUNYA VACCINE CANDIDATE (PRE-BLA STAGE) in Florida on Wednesday 25 May. " Travel and Tropical Medicine expert Bradley A. Connor, M.D. (Weill Cornell Medical College, New York Presbyterian), who will discuss the unmet medical need to protect travelers and prevent outbreaks of mosquito-borne chikungunya virus (CHIKV). Juan Carlos Jaramillo, M.D., Valneva's Chief Medical Officer will also provide an overview and update on VLA1553, the world's most clinically advanced CHIKV vaccine candidate, including key pivotal data comprising its FDA biologics license application (BLA), which Valneva expects to file in H2 2022. If approved, VLA1553 will be the first and only CHIKV vaccine available worldwide.
Quelle. who.int |